Prime Medicine PRME Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -4,498.1%+2,289pp | -6,787.4%— | —— | —— | |
| Net margin | -4,342.4%+2,224pp | -6,566.6%— | —— | —— | |
| EBITDA margin | -4,340%+2,242pp | -6,581.9%— | —— | —— | |
| Free cash flow margin | -3,607.4%— | —— | —— | —— | |
| Returns | |||||
| Return on equity | -146.8%-9.9pp | -136.9%-48.7pp | -88.2%— | —— | |
| Return on assets | -62.8%+16.9pp | -79.7%-8.2pp | -71.5%-34.7pp | -36.8%— | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×— | 0×— | 0×— | |
| Liquidity | |||||
| Current ratio | 4.8×-0.7× | 5.6×+3.0× | 2.5×-8.6× | 11.1×+6.4× | |
| Quick ratio | 4.8×-0.7× | 5.6×+3.0× | 2.5×-8.6× | 11.1×+6.4× | |
| Cash ratio | 2×-3.1× | 5.2×+4.2× | 1×-6.6× | 7.5×+4.1× | |
| Leverage | |||||
| Debt-to-equity | 1×+0.7× | 0.3×+0.2× | 0.1×0.0× | 0.1×— | |
| Debt-to-assets | 0.3×+0.2× | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $0.81-37.1% | $1.29-11.7% | $1.46-84.3% | $9.33+177% | |
| Valuation | |||||
| Market capitalization | $574.36M+111% | $382.99M-55.6% | $862.76M-37.4% | $1.38B— | |
| Enterprise value | $611.08M+113% | $227.25M-72.3% | $821.32M-31.9% | $1.21B— | |
| Price / sales | 124×— | 128.4×— | —— | —— | |
| Price / book | 7.5×+4.9× | 2.5×-4.0× | 6.5×+2.1× | 4.4×— | |
| EV / sales | 143.8×+67.6× | 76.2×— | —— | —— | |
| Free cash flow yield | -27.6%— | —— | -20.2%-9.5pp | -10.7%— | |
| Earnings yield | -34.5%+39.8pp | -51.1%-28.2pp | -23%-14.1pp | -8.8%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Prime Medicine's ratios come from?
- Every ratio is computed from Prime Medicine's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
